Thiazide-type diuretics and beta-adrenergic blockers as first-line drug treatments for hypertension.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it.

1. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis.BMJ (Clinical research ed.) · 2013
   Pooled it
2. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.International journal of cardiology · 2010
   Trial
3. ALLHAT findings revisited in the context of subsequent analyses, other trials, and meta-analyses.Archives of internal medicine · 2009
   Trial
4. Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.American heart journal · 2009
   Trial
5. Beta-blockers for Hypertension: To Be or Not to Be a First-line Drug?Arquivos brasileiros de cardiologia · 2026
   Article
6. Design, Synthesis, Molecular Modeling, and Biological Evaluation of Novel Pyrimidine Derivatives as Potential Calcium Channel Blockers.Molecules (Basel, Switzerland) · 2023
   Article
7. Soluble (Pro)Renin Receptor as a Negative Regulator of NCC (NaHypertension (Dallas, Tex. : 1979) · 2021
   Article
8. Role of the alternative splice variant of NCC in blood pressure control.Channels (Austin, Tex.) · 2018
   Review
9. Predictors of the incidence of all-cause mortality and deaths due to diabetes and renal diseases among patients newly prescribed antihypertensive agents: a cohort study.International journal of cardiology · 2013
   Article
10. Guidelines for use of diuretics: a view from a member of JNC 7.Journal of clinical hypertension (Greenwich, Conn.) · 2012
    Article
11. β-blocker therapy and heart rate control during exercise testing in the general population: role of a common G-protein β-3 subunit variant.Pharmacogenomics · 2010
    Article
12. Impact of the ALLHAT/JNC7 Dissemination Project on thiazide-type diuretic use.Archives of internal medicine · 2010
    Article
13. Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction.Atherosclerosis · 2010
    Review
14. Prevention of heart failure with chlorthalidone in ALLHAT: placing the results into perspective.Journal of clinical hypertension (Greenwich, Conn.) · 2009
    Article
15. Pharmacogenetics of antihypertensive treatment: detailing disciplinary dissonance.Pharmacogenomics · 2009
    Review
16. Beta-Blockers in the Prevention and Treatment of Ischemic Heart Disease: Evidence and Clinical Practice.Heart views : the official journal of the Gulf Heart Association
    Review

Corrections and comments

• Commented on by
  Risk/benefit assessment of beta-blockers and diuretics precludes their use for first-line therapy in hypertension.2008

Authors and funding

2 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as